Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.07
0.2715.00%
At close: -
$2.09
0.020.97%
After Hours: Jun 20, 7:59 PM EDT
Comments
Loading...
Prime Medicine Analyst Ratings and Price Targets | NASDAQ:PRME | Benzinga
Prime Medicine Inc has a consensus price target of $15.19 based on the ratings of 16 analysts. The high is $25 issued by Jefferies on November 14, 2022. The low is $1.5 issued by Citigroup on May 27, 2025. The 3 most-recent analyst ratings were released by Citigroup, JMP Securities, and Chardan Capital on May 27, 2025, May 20, 2025, and May 19, 2025, respectively. With an average price target of $6.5 between Citigroup, JMP Securities, and Chardan Capital, there's an implied 211.00% upside for Prime Medicine Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
JMP Securities
Chardan Capital
Citizens Capital Markets
Guggenheim
1calculated from analyst ratings
Analyst Ratings for Prime Medicine
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/27/2025 | Buy Now | -28.23% | Citigroup | Samantha Semenkow32% | $10 → $1.5 | Downgrade | Buy → Neutral | Get Alert |
| 05/20/2025 | Buy Now | 187.08% | JMP Securities | Silvan Tuerkcan47% | $10 → $6 | Maintains | Market Outperform | Get Alert |
| 05/20/2025 | Buy Now | — | JP Morgan | Eric Joseph43% | — | Downgrade | Overweight → Neutral | Get Alert |
| 05/20/2025 | Buy Now | — | HC Wainwright & Co. | Arthur He36% | — | Downgrade | Buy → Neutral | Get Alert |
| 05/19/2025 | Buy Now | 474.16% | Chardan Capital | Geulah Livshits49% | $16 → $12 | Maintains | Buy | Get Alert |
| 03/20/2025 | Buy Now | 665.55% | Chardan Capital | Geulah Livshits49% | $15 → $16 | Maintains | Buy | Get Alert |
| 03/19/2025 | Buy Now | 378.47% | HC Wainwright & Co. | Arthur He36% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/04/2025 | Buy Now | 378.47% | Citizens Capital Markets | Silvan Tuerkcan47% | $10 → $10 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/03/2025 | Buy Now | 378.47% | HC Wainwright & Co. | Arthur He36% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/03/2025 | Buy Now | 617.7% | Chardan Capital | Geulah Livshits49% | $15 → $15 | Maintains | Buy | Get Alert |
| 12/10/2024 | Buy Now | 378.47% | JMP Securities | Silvan Tuerkcan47% | → $10 | Initiates | → Market Outperform | Get Alert |
| 12/03/2024 | Buy Now | 761.24% | Guggenheim | Debjit Chattopadhyay54% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 11/13/2024 | Buy Now | 617.7% | Chardan Capital | Geulah Livshits49% | $17 → $15 | Maintains | Buy | Get Alert |
| 11/13/2024 | Buy Now | 378.47% | HC Wainwright & Co. | Arthur He36% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 10/25/2024 | Buy Now | 378.47% | HC Wainwright & Co. | Arthur He36% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 10/02/2024 | Buy Now | 378.47% | HC Wainwright & Co. | Arthur He36% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2024 | Buy Now | 378.47% | HC Wainwright & Co. | Arthur He36% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/20/2024 | Buy Now | 378.47% | HC Wainwright & Co. | Arthur He36% | → $10 | Initiates | → Buy | Get Alert |
| 05/16/2024 | Buy Now | 378.47% | Citigroup | Samantha Semenkow32% | → $10 | Upgrade | Neutral → Buy | Get Alert |
| 05/13/2024 | Buy Now | 617.7% | JP Morgan | Eric Joseph43% | $16 → $15 | Maintains | Overweight | Get Alert |
| 05/07/2024 | Buy Now | 617.7% | Jefferies | Maury Raycroft33% | $23 → $15 | Assumes | Buy → Buy | Get Alert |
| 04/23/2024 | Buy Now | 474.16% | Wedbush | David Nierengarten60% | $12 → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 04/22/2024 | Buy Now | 713.4% | Chardan Capital | Geulah Livshits49% | → $17 | Initiates | → Buy | Get Alert |
| 04/08/2024 | Buy Now | — | TD Cowen | Joseph Thome26% | — | Initiates | → Buy | Get Alert |
| 04/03/2024 | Buy Now | 474.16% | Wedbush | David Nierengarten60% | → $12 | Initiates | → Outperform | Get Alert |
| 04/02/2024 | Buy Now | 474.16% | Wedbush | David Nierengarten60% | → $12 | Initiates | → Outperform | Get Alert |
| 03/08/2024 | Buy Now | 665.55% | JP Morgan | Eric Joseph43% | $26 → $16 | Maintains | Overweight | Get Alert |
| 03/05/2024 | Buy Now | 856.94% | Guggenheim | Debjit Chattopadhyay54% | $24 → $20 | Maintains | Buy | Get Alert |
| 12/08/2023 | Buy Now | 378.47% | Citigroup | Samantha Semenkow32% | → $10 | Initiates | → Neutral | Get Alert |
| 11/07/2023 | Buy Now | 1144.02% | JP Morgan | Eric Joseph43% | $27 → $26 | Maintains | Overweight | Get Alert |
| 10/09/2023 | Buy Now | 809.09% | BMO Capital | Kostas Biliouris33% | → $19 | Initiates | → Outperform | Get Alert |
| 09/06/2023 | Buy Now | 856.94% | JonesTrading | Justin Walsh41% | → $20 | Initiates | → Buy | Get Alert |
| 08/14/2023 | Buy Now | 809.09% | Morgan Stanley | Matthew Harrison61% | $21 → $19 | Maintains | Equal-Weight | Get Alert |
| 07/31/2023 | Buy Now | 1048.33% | Guggenheim | Debjit Chattopadhyay54% | → $24 | Initiates | → Buy | Get Alert |
| 04/18/2023 | Buy Now | 761.24% | Stifel | Dae Gon Ha49% | → $18 | Initiates | → Buy | Get Alert |
| 01/24/2023 | Buy Now | 904.78% | Morgan Stanley | Matthew Harrison61% | $23 → $21 | Maintains | Equal-Weight | Get Alert |
| 11/14/2022 | Buy Now | 1191.87% | JP Morgan | Eric Joseph43% | → $27 | Initiates | → Overweight | Get Alert |
| 11/14/2022 | Buy Now | 1096.17% | Jefferies | Eun Yang33% | → $25 | Initiates | → Buy | Get Alert |
| 11/14/2022 | Buy Now | 1000.48% | Morgan Stanley | Matthew Harrison61% | → $23 | Initiates | → Equal-Weight | Get Alert |
| 11/14/2022 | Buy Now | 952.63% | Goldman Sachs | Salveen Richter51% | → $22 | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for Prime Medicine (PRME) stock?
The latest price target for Prime Medicine (NASDAQ:PRME) was reported by Citigroup on May 27, 2025. The analyst firm set a price target for $1.50 expecting PRME to fall to within 12 months (a possible -28.23% downside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Prime Medicine (PRME)?
The latest analyst rating for Prime Medicine (NASDAQ:PRME) was provided by Citigroup, and Prime Medicine downgraded their neutral rating.
When was the last upgrade for Prime Medicine (PRME)?
The last upgrade for Prime Medicine Inc happened on May 16, 2024 when Citigroup raised their price target to $10. Citigroup previously had a neutral for Prime Medicine Inc.
When was the last downgrade for Prime Medicine (PRME)?
The last downgrade for Prime Medicine Inc happened on May 27, 2025 when Citigroup changed their price target from $10 to $1.5 for Prime Medicine Inc.
When is the next analyst rating going to be posted or updated for Prime Medicine (PRME)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prime Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prime Medicine was filed on May 27, 2025 so you should expect the next rating to be made available sometime around May 27, 2026.
Is the Analyst Rating Prime Medicine (PRME) correct?
While ratings are subjective and will change, the latest Prime Medicine (PRME) rating was a downgraded with a price target of $10.00 to $1.50. The current price Prime Medicine (PRME) is trading at is $2.09, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
